MarketVIEW: Staphylococcus aureus vaccines (CAT No: VAMV002)VacZine AnalyticsApril 1, 2010 35 Pages - SKU: VZAN2625150 |
| Staphylococcus aureus (S.aureus) is an opportunistic pathogen and a major cause of patient morbidity and mortality, especially in “at risk” populations. Prophylatic vaccines could prevent S.aureus infections and become cost effective in achieving savings from expensive infection control interventions e.g. MRSA screening on admission. Although all major companies have now announced S.aureus vaccine programs, Merck & Co (Intercell AG) are the most advanced (Phase II/III). If successful Merck & Co (Intercell AG) are predicted to be first to market in 2013/2014 potentially defining a highly lucrative new market category.
This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast within target nosocomial populations until 2030. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on nosocomial vaccines. Please note: this is delivered as a Zip file. |
Related Markets
Infectious Diseases Reports
- Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative Pathogens Offer Significant Revenue Potential
- Global Infectious Disease Treatment Market 2011-2014
- World Market for Anti-Infectives: Antifungals, Antibacterials and Antivirals (Treatments for HIV, HBV, HCV, Urinary Tract, Respiratory, Candidiasis and Other Infections)
- Global Infectious Disease Market Outlook: Facilities, Test Volume, and Sales Forecasts by Country
- Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast
